Elliott Management has built a large stake in GlaxoSmithKline

I have been buying GlaxoSmithKline stock ahead of the proposed split. An activist hedge fund taking a large stake in the company suggests they want something different. Here is what I am doing now.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

According to the Financial Times, activist hedge fund Elliott Management has built a multibillion-pound stake in GlaxoSmithKline (LSE:GSK). The news broke today, and the GlaxoSmithKline share price is up 4.3% at the time of writing. Given that the broader FTSE 100 is up only 0.58%, and other large-cap pharma stock prices have budged only slightly, it’s reasonable to assume that Glaxo shareholders have taken the news well.

Activist hedge fund target

Elliott Management — which is headed up by billionaire investor Paul Singer — has a history of taking large stakes in companies that it feels are underperforming. It then uses its influence as a large shareholder to push the board to make changes that it thinks will increase shareholder value.

5 Stocks For Trying To Build Wealth After 50

One notable billionaire made 99% of his current wealth after his 50th birthday. And here at The Motley Fool, we believe it is NEVER too late to start trying to build your fortune in the stock market. Our expert Motley Fool analyst team have shortlisted 5 companies that they believe could be a great fit for investors aged 50+ trying to build long-term, diversified portfolios.

Click here to claim your free copy now!

The GlaxoSmithKline share price has been underperforming its peers. It is down a little under 20% over three years. In contrast, the share prices of AstraZeneca and Pfizer, two notable peers, are up around 60% and 20%, respectively. Therefore, GlaxoSmithKline becoming the target of an activist hedge fund like Elliott Management is not a big surprise.

What is surprising is that major changes are already underway at GlaxoSmithKline. Investors have argued for years that the GlaxoSmithKline share price would do better if the company were to split. Investors calling for such a change are getting what they wanted.

What is Elliott Management after?

GlaxoSmithKline is due to split in 2022. The cash cow consumer healthcare business will go it alone with higher leverage and probably pay a stable dividend. The riskier biopharma business, dubbed ‘New Glaxo’, should emerge with lower debt and be able to invest heavily in a pipeline of new drugs.

GlaxoSmithKline told its shareholders about this plan over a year ago. Today’s announcement that Elliott Management has built a large stake suggests it is unhappy with the plan in part or in full. There is concern that the current CEO of GlaxoSmithKline, who previously has a successful tenure at personal care company L’Oréal, plans to head up the biopharma business after the split. The consumer healthcare division is thought to be better suited to the current CEO’s skill set.

It’s worth noting that GlaxoSmithKline has issued a dividend warning. After the split, the aggregate dividend is likely to be lower than the 80p paid for 2019. Perhaps this could be reason enough for Elliott to lobby against the company considering a lower payout.

It has also been suggested that GlaxoSmithKline’s sluggishness in developing a coronavirus vaccine, given its vaccine business is the jewel in its crown, is a motivating factor apart from the split. It’s worth noting that GlaxoSmithKline is collaborating on at least two Covid-19 vaccines at present.

GlaxoSmithKline share price

Without knowing what Elliott management wants, it’s impossible to speculate on the long-term effects of the activist hedge fund’s involvement on the GlaxoSmithKline share price. I am in favour of the split. Naturally, I would rather Elliott did not derail it. But, I can see the merits of arguing for the CEO to move to control the consumer healthcare business. As for vaccines, playing the long game might have been a shrewd move. Rolling vaccines out in record time have caused difficulties for others. It looks like Covid-19 will require multiple vaccines for quite some time.

Until I know more, I am continuing to buy GlaxoSmithKline shares ahead of the anticipated split.

More on Investing Articles

Tired woman sleeping on London underground
Investing Articles

5 steps to monthly passive income streams of £500

Aiming for regular passive income streams, our writer walks through five key steps he would take.

Read more »

Business people shaking hands
Investing Articles

Director dealings: HSBC, National Grid, Taylor Wimpey

Director dealings can indicate whether a company's doing well. So, here are this week's director dealings from three of the…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

2 lesser-known stocks with 10% dividend yields!

With sky-high inflation, sizeable dividend yields can help my portfolio grow. These two stocks are paying 10% on average.

Read more »

Businessman pulling out wooden brick from toppling stack
Investing Articles

Is the Woodbois share price a bargain – or a value trap?

The Woodbois share price has seen big swings recently. Our writer considers why and explains his response.

Read more »

Electric cars charging in station
Investing Articles

Here’s why NIO stock is my top EV pick!

NIO stock had been one of the worst-performing shares over the last year, but it appears to have bottomed out.…

Read more »

Risk reward ratio / risk management concept
Investing Articles

The JD Wetherspoon share price has fallen 45% — should I load up?

The JD Wetherspoon share price has shed almost half its value in the past year. Should our writer buy another…

Read more »

Light trails from traffic moving down The Mound in central Edinburgh, Scotland during December
Investing Articles

Down 50%, is the Scottish Mortgage share price a bargain in plain sight?

The Scottish Mortgage share price has lost half its value in recent months. Is it now a bargain for our…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

A cheap UK share for the cybersecurity boom!

I'm backing this UK share after its share price collapsed this week. In fact, I've recently added this cybersecurity stock…

Read more »